跳到正文
登录

公司

Nexus Pharmaceuticals, LLC

打开结构图

简介

总部
US

Nexus Pharmaceuticals, LLC 的结构

Nexus Pharmaceuticals, LLC

公司

2 个关联
约束监管与敞口
归属投资与持股
关系出现时间2026
Nexus Pharmaceuticals, LLC公司 · 2 个关联
第 1 层

归属投资与持股1

约束监管与敞口1

在关系网络中的位置

第 63518 位，共 104260 个前 61%

1 条直接关系

所在群组共 5 个紧密关联的对象，核心是

PAI PharmaSterile and ready-to-use pharmaceutical productsOlympus PartnersOral liquid medicines

本周新增关系

按有证据的公开关系计算，每天更新。

关系

公司之间的资金

谁投资、持有、收购或为谁融资，来自 AiSeek 有证据的关系。

PAI Pharma收购Nexus Pharmaceu…

流入Nexus Pharmaceuticals, LLC

线只表示这条关系存在以及方向，粗细不代表金额；圆点移动只是为了指示方向。

箭头表示关系方向，可按业务类别筛选。

  • PAI Pharma收购 →Nexus Pharmaceuticals, LLC
    公司 · PAI Pharma证据 1
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-13 02:00
      PAI Pharma ("PAI"), a portfolio company of Olympus Partners, and a leading U.S. developer, manufacturer, and marketer of oral liquid medicines, and Ready-To-Use ("RTU") sterile injectable and hospital-focused products, today announced the acquisition of Nexus Pharmaceuticals, LL…
      查看来源
  • Nexus Pharmaceuticals, LLC服务于 →hospitals
    产业 · hospitals证据 1
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-13 02:00
      Nexus brings an established commercial portfolio of over 20 hospital injectable products, deep customer relationships, and extensive expertise in developing and commercializing critical therapies.
      查看来源
  • Nexus Pharmaceuticals, LLC位于 →United States
    地区 · United States证据 1
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-11-13 02:00
      Nexus Pharmaceuticals is a U.S. based specialty pharmaceutical company
      查看来源

显示第 1 至 3 条，共 3 条

结论

结合来源阅读结论，展开条目查看证据。

事实证据 1
位于United States

Nexus Pharmaceuticals is a U.S. based specialty pharmaceutical company

PR Newswire news releases · 2026-11-13 02:00

查看证据
  • 公司披露PR Newswire news releases2026-11-13 02:00
    Nexus Pharmaceuticals is a U.S. based specialty pharmaceutical company
    查看来源
事实证据 1
收购PAI Pharma

PAI Pharma ("PAI"), a portfolio company of Olympus Partners, and a leading U.S. developer, manufacturer, and marketer of oral liquid medicines, and Ready-To-Use ("RTU") sterile injectable and hospital-focused products, today announced the acquisition of Nexus Pharmaceuticals, LL…

PR Newswire news releases · 2026-11-13 02:00

查看证据
  • 公司披露PR Newswire news releases2026-11-13 02:00
    PAI Pharma ("PAI"), a portfolio company of Olympus Partners, and a leading U.S. developer, manufacturer, and marketer of oral liquid medicines, and Ready-To-Use ("RTU") sterile injectable and hospital-focused products, today announced the acquisition of Nexus Pharmaceuticals, LL…
    查看来源
事实证据 1
服务于hospitals

Nexus brings an established commercial portfolio of over 20 hospital injectable products, deep customer relationships, and extensive expertise in developing and commercializing critical therapies.

PR Newswire news releases · 2026-11-13 02:00

查看证据
  • 公司披露PR Newswire news releases2026-11-13 02:00
    Nexus brings an established commercial portfolio of over 20 hospital injectable products, deep customer relationships, and extensive expertise in developing and commercializing critical therapies.
    查看来源

显示第 1 至 3 条，共 3 条

市场与估值

估值数据需要 Pro 或 Research。

升级到 Pro 解锁

推荐一个值得监测的页面

这家公司有哪些页面值得盯着，比如价格、更新日志、条款或招聘页？推荐给我们。每条推荐都有人看；收录后，这个页面会为所有读者一起监测，并且只有连续两次抓取一致才算一次变化。

登录后推荐页面

暂无: 公司信号 · 财务数据 · 披露文件 · 据点 · 业绩指引